Key Takeaways RVMD reported a Q4 2025 loss of $1.86 per share, wider than estimates, with no revenues.Revolution Medicines expects 2026 operating expenses of $1.6B-$1.7B, including stock-based pay.Revolution Medicines advanced daraxonrasib into multiple late-stage studies in PDAC and NSCLC.Revolution Medicines (RVMD) reported a fourth-quarter 2025 loss of $1.86 per share, wider than the Zacks Consensus Estimate of a loss of $1.56. The company had incurred a loss of $1.12 in the year-ago quarter.Currently, R ...